Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$20.80 USD
-0.34 (-1.61%)
Updated Sep 20, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Arrowhead Pharmaceuticals, Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 241 | 243 | 138 | 88 | 169 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 241 | 243 | 138 | 88 | 169 |
Selling & Adminstrative & Depr. & Amort Expenses | 446 | 422 | 287 | 181 | 108 |
Income After Depreciation & Amortization | -205 | -179 | -149 | -93 | 61 |
Non-Operating Income | 17 | 6 | 8 | 9 | 7 |
Interest Expense | 18 | 0 | 0 | 0 | 0 |
Pretax Income | -206 | -173 | -141 | -85 | 68 |
Income Taxes | 3 | 4 | 0 | 0 | 0 |
Minority Interest | -4 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -209 | -176 | -141 | -85 | 68 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -205 | -176 | -141 | -85 | 68 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -195 | -165 | -141 | -87 | 67 |
Depreciation & Amortization (Cash Flow) | 10 | 13 | 9 | 6 | 6 |
Income After Depreciation & Amortization | -205 | -179 | -149 | -93 | 61 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 106.75 | 105.43 | 103.75 | 100.72 | 98.61 |
Diluted EPS Before Non-Recurring Items | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 |
Diluted Net EPS (GAAP) | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 |
Fiscal Year end for Arrowhead Pharmaceuticals, Inc falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 3.55 | 16.10 | 15.83 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 3.55 | 16.10 | 15.83 |
SG&A, R&D, and Dept/Amort Expenses | 176.14 | 126.19 | 140.10 | 124.42 | 118.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | -176.14 | -126.19 | -136.55 | -108.32 | -102.70 |
Non-Operating Income | 7.26 | 6.44 | 3.22 | 7.45 | 4.48 |
Interest Expense | 5.09 | 7.24 | 5.37 | 8.11 | 5.16 |
Pretax Income | -173.98 | -127.00 | -138.69 | -108.99 | -103.38 |
Income Taxes | 0.00 | 0.00 | -3.31 | 2.03 | 0.74 |
Minority Interest | -3.18 | -1.70 | -2.51 | -1.34 | -1.18 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -173.98 | -127.00 | -135.38 | -111.02 | -104.13 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -170.79 | -125.30 | -132.86 | -109.68 | -102.95 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 124.20 | 123.29 | 107.42 | 106.88 | 107.00 |
Diluted EPS Before Non-Recurring Items | -1.38 | -1.02 | -1.24 | -1.03 | -0.96 |
Diluted Net EPS (GAAP) | -1.38 | -1.02 | -1.24 | -1.02 | -0.96 |